Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial

Kaixiong Tao, Zhenyu Lin, Peng Zhang, Pan Chi, Yi Xiao, Zhiguo Hou, Ximing Xu, Aimin Zhang, Xingfeng Qiu, Junxin Wu, Ying Yuan, Zhenning Wang, Xiujuan Qu, Xin Li, Xiu Nie, Ming Yang, Kailin Cai, Zheng Wang, Weikang Zhang, Ying Huang, Zhen Sun, Rongrong Zheng, Feng Zhao, Chuyi Han, Tao Zhang

Open source

DOI
10.1016/s1470-2045(26)00446-8
Published
2026-11
Container
The Lancet Oncology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00446-8,
  title = {Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial},
  author = {Kaixiong Tao and Zhenyu Lin and Peng Zhang and Pan Chi and Yi Xiao and Zhiguo Hou and Ximing Xu and Aimin Zhang and Xingfeng Qiu and Junxin Wu and Ying Yuan and Zhenning Wang and Xiujuan Qu and Xin Li and Xiu Nie and Ming Yang and Kailin Cai and Zheng Wang and Weikang Zhang and Ying Huang and Zhen Sun and Rongrong Zheng and Feng Zhao and Chuyi Han and Tao Zhang},
  year = {2026},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(26)00446-8},
  url = {https://doi.org/10.1016/s1470-2045(26)00446-8}
}

RIS

TY  - JOUR
TI  - Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
AU  - Kaixiong Tao
AU  - Zhenyu Lin
AU  - Peng Zhang
AU  - Pan Chi
AU  - Yi Xiao
AU  - Zhiguo Hou
AU  - Ximing Xu
AU  - Aimin Zhang
AU  - Xingfeng Qiu
AU  - Junxin Wu
AU  - Ying Yuan
AU  - Zhenning Wang
AU  - Xiujuan Qu
AU  - Xin Li
AU  - Xiu Nie
AU  - Ming Yang
AU  - Kailin Cai
AU  - Zheng Wang
AU  - Weikang Zhang
AU  - Ying Huang
AU  - Zhen Sun
AU  - Rongrong Zheng
AU  - Feng Zhao
AU  - Chuyi Han
AU  - Tao Zhang
PY  - 2026
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(26)00446-8
UR  - https://doi.org/10.1016/s1470-2045(26)00446-8
ER  - 

APA

Tao, K., Lin, Z., Zhang, P., Chi, P., Xiao, Y., Hou, Z., Xu, X., Zhang, A., Qiu, X., Wu, J., Yuan, Y., Wang, Z., Qu, X., Li, X., Nie, X., Yang, M., Cai, K., Wang, Z., Zhang, W., Huang, Y., Sun, Z., Zheng, R., Zhao, F., Han, C., & Zhang, T. (2026). Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00446-8

Source records